FOR IMMEDIATE RELEASE FOR MEDICAL PROFESSIONALS ONLY
October 1, 2007
Contact: Howard Simon
Phone: 888-737-3588 ext 802
(Redondo Beach, CA) The most exciting research in years was presented at the American Society of Clinical Oncology (ASCO) meeting in June 2007.
Avemar, a nutritional supplement, used alone, was shown to have a greater tumor inhibition effect on both estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer than standard endocrine drug therapies. Used in conjunction with these anti-hormone drugs, the effect of Avemar was less than when used alone, with one exception. The combination of Avemar + Exemestane produced a cancer inhibition effect of 60%, 10% greater than Avemar by itself. Avemar did, however, enhance the anti-cancer effect of Tamoxifen, Exemestane and Anastrozole by 5 – 13%.
Avemar has been certified as GRAS (Generally Recognized As Safe), shown to have the safety profile of bread, with the most commonly reported side effect – it tastes bad.
The American Society of Clinical Oncology (ASCO) is regarded as the world’s premier conference on cancer. It is attended by more than 25,000 doctors, scientists and others working in the field. Among the 4,000 abstracts accepted for the conference is this new research showing that Avemar, an extract of wheat germ, inhibits both estrogen-positive and estrogen-negative breast tumors, and enhances the effects of the widely used endocrine treatments Tamoxifen, Exemestand and Anastrozole.
The cancer fighting benefits of the wheat germ extract, Avemar, have previously been demonstrated in several tumor models. In the breast cancer cell line commonly used to screen agents for their effect on estrogen-positive breast cancers (known as MCF-7), the wheat germ extract was shown to enhance the anti-cancer effects of Tamoxifen. This is the model that was initially used to validate Tamoxifen. In the current study, Andras Telekes, M.D., Ph.D., head physician at the Hungarian National Institute of Oncology, and colleagues, implanted estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer cell lines from humans and mice into female mice and monitored tumor growth.
Tamoxifen (sold under the brand names Nolvadex, Istubal, and Valodex), Exemestane (sole under the brand name Aromasin), and Anastrozole (sold under the brand name Arimidex), all work against breast cancer by blocking either the production or uptake of the female hormone estrogen. Each drug by itself inhibited estrogen receptor-positive cell lines, but none worked as well as Avemar by itself.
Against the mouse derived estrogen receptor-positive (ER+) cell line, MXT, compared to controls, Avemar inhibited growth by 50%, Exemestane by 46.5%, Tamoxifen by 34%, and Anastrozole by 29.3%. Against the human ER+ cell line, T47T, Avemar inhibited growth breast cancer cell growth by 49%, Tamoxifen by 42%, Exemestane by 25% and Anastrazole by 25%. The effect of each agent was enhanced by 5 to 13% when combined with Avemar. The best result was obtained from the combination of Exemestane and Avemar, inhibiting both the mouse and human derived ER+ breast tumors by 60%.
Effects against estrogen receptor-negative (ER-) breast cancer were measured with the human derived, MDA-MB-231 cell line. Since prior research shows that these estrogen blocking drugs are not effective against ER- breast cancers, they were not tested in this tumor model. However, Avemar did inhibit the growth of the ER-negative MDA-MB-231 breast tumors significantly (52%), suggesting to researchers that the mechanism(s) by which Avemar works is different from that of the anti-estrogen drugs, and is independent of a breast tumor’s estrogen receptor status.
The results of this study are consistent with earlier cell, animal and human studies in which the tumor growth-inhibitory effects of Avemar were investigated. Of particular interest was the inhibition of breast tumor growth in the animals regardless of whether the cell type was ER+ or ER-. This suggests that the mechanisms of action by which Avemar inhibits growth in breast tumors are the same mechanisms as those that inhibited tumor growth in multiple other cell lines and tumor types against which the extract has been tested (including other breast, lung, pancreatic, colon, melanoma, leukemia, and pancreatic cancers). Avemar has been demonstrated to work by at least six different mechanisms. The most important of these growth-inhibiting mechanisms is Avemar’s interference with excess use of glucose by cancer cells (the Warburg effect) interfering with the production of MHC-1 presentation by tumor cells which enhances the ability of Natural Killer (NK) cells to target and kill cancer cells.
Avemar is produced by Biromedicina RT of Budapest, Hungary through the fermentation of wheat germ by baker’s yeast according to a patented process (U.S. no. 6,355,474) and standardized on the compound methoxy-substituted benzoquinones. Research, which led to its development, was initiated by Hungarian biochemist Albert Szent-Gyorgyi, whose work published in the 1980’s showed that wheat germ derived methoxy-substituted benzoquinones provided anti-cancer effects. Studies of Avemar, including clinical trials conducted in Hungary, Russia, Italy, Israel and the US have led to Hungarian Ministry of Health approval of Avemar as a “medical food,” indicated for the treatment of colorectal and other cancers.
Avemar has recently been affirmed as GRAS (Generally Recognized As Safe), an FDA process that allows the use of compounds in foods, beverages and dietary supplements. It is presently available as a dietary supplement instant drink mix, under the brand name Ave’ to medical professionals through Rejuvenation Science in Redondo Beach, CA., www.Rejuvenation-Science.com, 888-737-3588. According to Scott Broder, host of American Health Radio, “Rejuvenation Science offers a panoply of eclectic products that could help you maintain your good health.”
Twenty-six research studies are available via the U.S. National Institutes of Health - National Library of Medicine website, www.pubmed.gov using the search terms “Avemar” and/or “fermented wheat germ” or by contacting Rejuvenation Science for a printed publication, a CD audio and PowerPoint presentation.
Rejuvenation Science, 811 N. Catalina Ave., Suite 3208, Redondo Beach, CA 90277
310-798-2830 ext 802
howard (at) rejuvenation-science (dot) com.